Emerging infectious diseases pose a global threat to human and animal health, and the problem is likely to worsen, warns an expert in this weeks British Medical Journal.
The recent emergence of diseases such as AIDS, SARS and avian flu have catapulted emerging infectious diseases to the top of the medical and political agendas, and have highlighted the importance of wildlife as reservoirs or vectors for disease, writes Dr. Andrew Cunningham.
Of pathogens causing emerging infectious diseases, 75 percent are zoonotic, with wildlife being an increasingly important source. But why are we now seeing an apparently rapid increase in the emergence of new zoonoses from wildlife?
One of the major drivers is closer human contact with wildlife, primarily caused by human encroachment into, and modification of, wildlife habitat. For example, Ebola virus outbreaks often are linked to hunting for bushmeat or to mining development, and the AIDS pandemic originated from human encroachment into African forests for food.
The rise in international trade and travel is also important. The emergence of West Nile virus in North America, and AIDS and SARS globally, for example, arose from such travel and trade.
This globalization of people and products is difficult to control and is largely related to increasing air transportation. With world air travel expected to grow at about 5 percent a year for at least the next 20 years, the problem of emerging infectious diseases will continue to grow, he warns.
Emerging infectious diseases are not only a problem for human health but are a major threat to animal welfare and to species conservation. Some emerging infectious diseases also threaten domesticated species.
Through emerging infectious diseases, therefore, the medical, veterinary, and wildlife conservation professions, share a common agenda. The problem is not small, and tackling it will not be easy, but recognizing a common problem is, at least, a start, he concludes.
Reference: Editorial: A walk on the wild side: emerging wildlife diseases BMJ. Vol. 331, pp 1214-5.
Source: British Medical Journal
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.